Lista de obras -

A 71-year-old woman with decreased vision, nyctalopia, and peripheral vision loss

artículo científico publicado en 2016

A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors

artículo científico publicado en 2019

A Melanoma Brain Metastasis with a Donor-Patient Hybrid Genome following Bone Marrow Transplantation: First Evidence for Fusion in Human Cancer

artículo científico publicado en 2013

A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia

artículo científico publicado en 2004

A Phase III study (CheckMate 238) of adjuvant immunotherapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage IIIb/c or stage IV melanoma (MEL) in patients (pts) at high risk for recurrence

artículo científico publicado en 2015

A Serum Protein Signature Associated with Outcome After Anti-PD1 Therapy in Metastatic Melanoma.

artículo científico publicado en 2017

A clinical development paradigm for cancer vaccines and related biologics

artículo científico publicado en 2007

A novel anti-melanoma SRC-family kinase inhibitor

A phase 2 trial of dasatinib in advanced melanoma ⬇️

artículo científico publicado el 29 de noviembre de 2010

A phase I and pharmacokinetic study of VNP40101M, a new alkylating agent, in patients with advanced or metastatic cancer

artículo científico publicado en 2005

A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive mye

artículo científico publicado en 2007

A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer

artículo científico publicado en 2004

Advances in the systemic treatment of metastatic melanoma.

artículo científico

Advances in the treatment of metastatic melanoma: new immunomodulatory agents

artículo científico publicado en 2012

Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer

artículo científico publicado en 2013

Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma

scientific article published on 30 August 2016

Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)

scientific article published on 21 May 2020

Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design

artículo científico publicado en 2020

Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy

artículo científico publicado en 2020

Betting on immunotherapy for melanoma

artículo científico publicado en 2009

Biology of advanced uveal melanoma and next steps for clinical therapeutics

artículo científico publicado en 2014

Blockade of the B7-H1/PD-1 pathway as a basis for combination anticancer therapy

artículo científico

Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy

artículo científico publicado en 2011

C-Raf is associated with disease progression and cell proliferation in a subset of melanomas

scientific article published on 08 September 2009

Cancer Immunotherapy: Past Progress and Future Directions

artículo científico publicado en 2015

Challenges in Conducting Clinical Research on Patients With Advanced Melanoma

artículo científico publicado en 2017

Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites

artículo científico publicado en 2015

Chitinase-like proteins in lung injury, repair, and metastasis

artículo científico publicado en 2012

Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology

artículo científico publicado en 2018

Clinical Experiences With Anti-CD137 and Anti-PD1 Therapeutic Antibodies ⬇️

artículo científico publicado el 1 de octubre de 2010

Combination Strategies PD-1/PD-L1 Antagonists.

artículo científico publicado en 2018

Combination immunotherapy: Where do we go from here?

artículo científico publicado en 2015

Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo

artículo científico publicado en 2014

Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor

artículo científico publicado en 2014

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

artículo científico publicado en 2015

Distinct immunologic changes in vivo following combination versus individual PD-1 or CTLA-4 checkpoint blockade in human cancer

Early B cell changes predict autoimmunity following combination immune checkpoint blockade

artículo científico publicado en 2018

Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis

artículo científico publicado en 2016

Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management

artículo científico publicado en 2017

Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas

artículo científico publicado en 2015

Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma

artículo científico publicado en 2012

Expression of tumor necrosis factor--related apoptosis-inducing ligand receptors 1 and 2 in melanoma

artículo científico publicado en 2006

First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study

artículo científico publicado en 2017

Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th 2010"

artículo científico publicado en 2011

Immune Modulation Therapy and Imaging: Workshop Report

artículo científico publicado en 2017

Immune therapy of metastatic melanoma developing after allogeneic bone marrow transplant

artículo científico publicado en 2015

Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma

artículo científico publicado en 2016

In vitro studies of dasatinib, its targets and predictors of sensitivity ⬇️

artículo científico publicado el 1 de abril de 2011

Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032.

artículo científico publicado en 2010

Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205.

artículo científico publicado en 2014

Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab

artículo científico publicado en 2011

Integrative analysis of epigenetic modulation in melanoma cell response to decitabine: clinical implications

artículo científico publicado en 2009

Interlesional diversity of T cell receptors in melanoma with immune checkpoints enriched in tissue-resident memory T cells

artículo científico publicado en 2016

Introducing a New Series: Immunotherapy Facts and Hopes.

artículo científico publicado en 2018

Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial

artículo científico publicado en 2012

Ipilimumab-induced perforating colitis

artículo científico publicado en 2013

Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial

artículo científico publicado en 2018

Markers of inflammation are associated with clinical outcomes in patients with metastatic renal cell carcinoma treated with nivolumab.

artículo científico publicado en 2015

Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015

artículo científico publicado en 2016

Melanoma brain metastases: is it time to reassess the bias?

artículo científico publicado en 2011

Melanoma: a model for testing new agents in combination therapies

artículo científico publicado en 2010

MicroRNA signatures differentiate melanoma subtypes

artículo científico publicado en 2011

Molecular Markers of Response to Treatment for Melanoma ⬇️

artículo científico publicado el 1 de marzo de 2011

Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study

artículo científico publicado en 2017

Nivolumab plus ipilimumab in advanced melanoma

artículo científico publicado en 2013

Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer

artículo científico publicado en 2015

PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells

artículo científico publicado en 2010

Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial

artículo científico publicado en 2016

Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab.

artículo científico publicado en 2014

Peripheral blood and tumor biomarkers in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab.

artículo científico publicado en 2013

Phase I Trial of Triapine-Cisplatin-Paclitaxel Chemotherapy for Advanced Stage or Metastatic Solid Tumor Cancers

artículo científico publicado en 2017

Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia

artículo científico publicado en 2003

Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion

artículo científico publicado en 2004

Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors ⬇️

artículo científico publicado el 15 de septiembre de 2003

Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia

artículo científico publicado en 2005

Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma

artículo científico publicado en 2002

Phase I study of the sequential combination of interleukin-12 and interferon alfa-2b in advanced cancer: evidence for modulation of interferon signaling pathways by interleukin-12.

artículo científico publicado en 2005

Phase I trial of daily triapine in combination with cisplatin chemotherapy for advanced-stage malignancies

artículo científico publicado en 2016

Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma

artículo científico publicado en 2014

Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors

artículo científico publicado en 2017

Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients ⬇️

artículo científico publicado el 1 de octubre de 2003

Plasma Markers for Identifying Patients with Metastatic Melanoma ⬇️

artículo científico publicado el 12 de abril de 2011

Pre-treatment patient selection for nivolumab benefit based on serum mass spectra

artículo científico publicado en 2015

Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy

artículo científico publicado en 2015

Programmed death ligand-1 expression in non-small cell lung cancer

artículo científico publicado en 2013

Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

artículo científico publicado en 2018

Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival

artículo científico publicado en 2012

Relative roles of targeted therapies and immunotherapies in melanoma.

artículo científico publicado en 2012

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

artículo científico publicado el 1 de diciembre de 2010

Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody

artículo científico publicado en 2016

Revisiting ribonucleotide reductase as a target to enhance radiation and chemotherapy anti-tumor activity

artículo científico publicado en 2003

Role of chitinase 3-like-1 and semaphorin 7a in pulmonary melanoma metastasis

artículo científico publicado en 2014

Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma

artículo científico publicado en 2016

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

artículo científico publicado en 2012

Systemic administration of an attenuated, tumor-targeting Salmonella typhimurium to dogs with spontaneous neoplasia: phase I evaluation

artículo científico publicado en 2005

The Phoenix Rises: The Rebirth of Cancer Immunotherapy

artículo científico publicado en 2017

The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization

artículo científico publicado en 2007

Therapeutic combinations of immune-modulating antibodies in melanoma and beyond

artículo científico

Tissue resident memory T cells create genetically distinct immune microenvironments within melanoma metastasis

artículo científico publicado en 2015

Toxicity and activity of a twice daily high-dose bolus interleukin 2 regimen in patients with metastatic melanoma and metastatic renal cell cancer

artículo científico publicado en 2008

Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome

artículo científico publicado en 2006

White Paper on Adoptive Cell Therapy for Cancer with Tumor-Infiltrating Lymphocytes: A Report of the CTEP Subcommittee on Adoptive Cell Therapy ⬇️

artículo científico publicado el 15 de febrero de 2011

Lista de obras de

A 71-year-old woman with decreased vision, nyctalopia, and peripheral vision loss

A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors

A Melanoma Brain Metastasis with a Donor-Patient Hybrid Genome following Bone Marrow Transplantation: First Evidence for Fusion in Human Cancer

A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia

A Phase III study (CheckMate 238) of adjuvant immunotherapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage IIIb/c or stage IV melanoma (MEL) in patients (pts) at high risk for recurrence

A Serum Protein Signature Associated with Outcome After Anti-PD1 Therapy in Metastatic Melanoma.

A clinical development paradigm for cancer vaccines and related biologics

A novel anti-melanoma SRC-family kinase inhibitor

A phase 2 trial of dasatinib in advanced melanoma ⬇️

A phase I and pharmacokinetic study of VNP40101M, a new alkylating agent, in patients with advanced or metastatic cancer

A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive mye

A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer

Advances in the systemic treatment of metastatic melanoma.

Advances in the treatment of metastatic melanoma: new immunomodulatory agents

Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer

Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma

Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)

Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design

Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy

Betting on immunotherapy for melanoma

Biology of advanced uveal melanoma and next steps for clinical therapeutics

Blockade of the B7-H1/PD-1 pathway as a basis for combination anticancer therapy

Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy

C-Raf is associated with disease progression and cell proliferation in a subset of melanomas

Cancer Immunotherapy: Past Progress and Future Directions

Challenges in Conducting Clinical Research on Patients With Advanced Melanoma

Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites

Chitinase-like proteins in lung injury, repair, and metastasis

Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology

Clinical Experiences With Anti-CD137 and Anti-PD1 Therapeutic Antibodies ⬇️

Combination Strategies PD-1/PD-L1 Antagonists.

Combination immunotherapy: Where do we go from here?

Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo

Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Distinct immunologic changes in vivo following combination versus individual PD-1 or CTLA-4 checkpoint blockade in human cancer

Early B cell changes predict autoimmunity following combination immune checkpoint blockade

Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis

Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management

Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas

Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma

Expression of tumor necrosis factor--related apoptosis-inducing ligand receptors 1 and 2 in melanoma

First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study

Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th 2010"

Immune Modulation Therapy and Imaging: Workshop Report

Immune therapy of metastatic melanoma developing after allogeneic bone marrow transplant

Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma

In vitro studies of dasatinib, its targets and predictors of sensitivity ⬇️

Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032.

Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205.

Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab

Integrative analysis of epigenetic modulation in melanoma cell response to decitabine: clinical implications

Interlesional diversity of T cell receptors in melanoma with immune checkpoints enriched in tissue-resident memory T cells

Introducing a New Series: Immunotherapy Facts and Hopes.

Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial

Ipilimumab-induced perforating colitis

Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial

Markers of inflammation are associated with clinical outcomes in patients with metastatic renal cell carcinoma treated with nivolumab.

Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015

Melanoma brain metastases: is it time to reassess the bias?

Melanoma: a model for testing new agents in combination therapies

MicroRNA signatures differentiate melanoma subtypes

Molecular Markers of Response to Treatment for Melanoma ⬇️

Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study

Nivolumab plus ipilimumab in advanced melanoma

Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer

PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells

Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial

Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab.

Peripheral blood and tumor biomarkers in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab.

Phase I Trial of Triapine-Cisplatin-Paclitaxel Chemotherapy for Advanced Stage or Metastatic Solid Tumor Cancers

Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia

Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion

Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors ⬇️

Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia

Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma

Phase I study of the sequential combination of interleukin-12 and interferon alfa-2b in advanced cancer: evidence for modulation of interferon signaling pathways by interleukin-12.

Phase I trial of daily triapine in combination with cisplatin chemotherapy for advanced-stage malignancies

Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma